Champions Oncology, Inc. (CSBR) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
CSBR Insider Trading Activity
CSBR Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Champions Oncology, Inc.
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Insider Activity of Champions Oncology, Inc.
Over the last 12 months, insiders at Champions Oncology, Inc. have bought $0 and sold $0 worth of Champions Oncology, Inc. stock.
On average, over the past 5 years, insiders at Champions Oncology, Inc. have bought $245,869 and sold $356,976 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $6,500 was made by Mendelson Daniel Newman (director) on 2024‑01‑12.
List of Insider Buy and Sell Transactions, Champions Oncology, Inc.
| 2024-01-12 | Mendelson Daniel Newman | director | 1,000 0.0071% | $6.50 | $6,500 | -27.12% | ||
| 2024-01-11 | Mendelson Daniel Newman | director | 2,000 0.0147% | $6.27 | $12,540 | -21.18% | ||
| 2024-01-10 | Mendelson Daniel Newman | director | 2,944 0.022% | $6.31 | $18,577 | -20.33% | ||
| 2024-01-09 | Mendelson Daniel Newman | director | 3,000 0.0221% | $6.25 | $18,750 | -21.47% | ||
| 2024-01-08 | Mendelson Daniel Newman | director | 1,000 0.0074% | $6.15 | $6,150 | -20.20% | ||
| 2024-01-05 | Mendelson Daniel Newman | director | 2,000 0.0146% | $6.09 | $12,180 | -19.22% | ||
| 2024-01-04 | Mendelson Daniel Newman | director | 3,000 0.0221% | $6.12 | $18,360 | -19.67% | ||
| 2024-01-03 | Mendelson Daniel Newman | director | 500 0.0035% | $5.83 | $2,915 | -20.33% | ||
| 2023-12-21 | Mendelson Daniel Newman | director | 2,500 0.0184% | $4.92 | $12,300 | -0.20% | ||
| 2023-12-20 | Mendelson Daniel Newman | director | 2,100 0.015% | $4.82 | $10,122 | -1.41% | ||
| 2023-12-19 | Mendelson Daniel Newman | director | 5,000 0.0384% | $4.75 | $23,750 | +7.46% | ||
| 2023-10-11 | Mendelson Daniel Newman | director | 5,000 0.0385% | $6.40 | $32,000 | -18.72% | ||
| 2023-10-10 | Mendelson Daniel Newman | director | 1,100 0.008% | $6.41 | $7,051 | -21.44% | ||
| 2023-10-06 | Mendelson Daniel Newman | director | 1,530 0.0114% | $6.48 | $9,914 | -22.02% | ||
| 2023-10-05 | Mendelson Daniel Newman | director | 2,000 0.0156% | $6.47 | $12,940 | -18.87% | ||
| 2023-10-04 | Mendelson Daniel Newman | director | 5,000 0.0386% | $6.40 | $32,000 | -20.16% | ||
| 2023-10-03 | Mendelson Daniel Newman | director | 2,500 0.019% | $6.30 | $15,750 | -19.75% | ||
| 2023-09-29 | Mendelson Daniel Newman | director | 4,000 0.0294% | $6.16 | $24,640 | -18.68% | ||
| 2023-09-28 | Mendelson Daniel Newman | director | 5,000 0.0379% | $6.22 | $31,100 | -16.94% | ||
| 2023-09-27 | Mendelson Daniel Newman | director | 1,500 0.0115% | $5.95 | $8,925 | -12.63% |
Insider Historical Profitability
| BROWN MICHAEL MAURICE | 10 percent owner | 22281040 161.1427% | $139.15M | 2 | 0 | |
| Battery Ventures IX, L.P. | 10 percent owner | 22281040 161.1427% | $139.15M | 2 | 0 | |
| Martell James | director | 2051828 14.8394% | $12.81M | 0 | 7 | |
| New Enterprise Associates 14, L.P. | 10 percent owner | 1713720 12.3941% | $10.7M | 0 | 1 | |
| ACKERMAN JOEL | director | 1021731 7.3894% | $6.38M | 10 | 1 | +66.05% |
| Morris Ronnie | CEO | 858878 6.2116% | $5.36M | 16 | 1 | +86.37% |
| Mendelson Daniel Newman | director | 198625 1.4365% | $1.24M | 30 | 2 | <0.0001% |
| BURKETT DOUGLAS D | President | 850 0.0061% | $5,308.25 | 3 | 0 | |
| Breitfeld Philip P. | director | 0 0% | $0 | 0 | 1 |
Historical Insider Profitability vs. Competitors
$30,470,407 | 140 | 20.39% | $89.85M | |
$4,968,419 | 139 | 5.13% | $85.97M | |
$49,091,668 | 110 | 13.11% | $88.84M | |
$2,600,095 | 110 | 13.50% | $75.58M | |
$22,608,361 | 93 | 3.94% | $83.4M | |
$671,363 | 44 | -16.23% | $83.76M | |
Champions Oncology, Inc. (CSBR) | $909,129 | 37 | 42.19% | $86.35M |
$140,938,207 | 36 | 14.75% | $91.84M | |
$53,912,175 | 35 | -8.02% | $79.22M | |
$7,147,964 | 34 | 24.78% | $91.51M | |
$26,678,853 | 21 | -5.95% | $75.27M | |
$277,862 | 15 | 59.79% | $90.84M | |
$135,589,307 | 10 | 32.46% | $86.89M | |
$272,982 | 6 | -28.53% | $91.92M | |
$45,000,000 | 6 | -31.22% | $83.56M | |
$401,951 | 4 | 57.41% | $90.85M | |
$4,256,958 | 4 | 22.95% | $77.64M | |
$40,000,000 | 3 | -16.24% | $85.39M | |
$1,250 | 1 | 278.21% | $93.58M |
CSBR Institutional Investors: Active Positions
| Increased Positions | 13 | +59.09% | 132,053 | +2.3% |
| Decreased Positions | 6 | -27.27% | 99,081 | -1.73% |
| New Positions | 6 | New | 82,673 | New |
| Sold Out Positions | 2 | Sold Out | 1,392 | Sold Out |
| Total Postitions | 29 | +31.82% | 6M | +0.57% |
CSBR Ownership Change vs Market
Institutional Investor Ownership
| Battery Management Corp. | $13,973.00 | 17.3% | 2.42M | 0 | 0% | 2024-12-31 |
| Nea Management Company, Llc | $9,888.00 | 12.24% | 1.71M | 0 | 0% | 2024-12-31 |
| Tocqueville Asset Management L.P. | $3,513.00 | 4.35% | 608,915 | -96,299 | -13.65% | 2024-12-31 |
| Vanguard Group Inc | $1,771.00 | 2.19% | 307,002 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $801.00 | 0.99% | 138,839 | +18,848 | +15.71% | 2024-12-31 |
| Blackrock, Inc. | $669.00 | 0.83% | 115,859 | -441 | -0.38% | 2025-03-31 |
| Morgan Stanley | $421.00 | 0.52% | 72,900 | +15,100 | +26.13% | 2024-12-31 |
| Geode Capital Management, Llc | $384.00 | 0.48% | 66,511 | +1,447 | +2.22% | 2024-12-31 |
| Northern Trust Corp | $312.00 | 0.39% | 53,994 | +12,923 | +31.46% | 2024-12-31 |
| Hightower Advisors, Llc | $227.00 | 0.28% | 39,308 | 0 | 0% | 2024-12-31 |